人类 p75 TNF 受体 IgG1抗体
Concentration (µg/mL)
1000 100 10 1
Infliximab 3 mg q8w Adalimumab 40 mg EOW Etanercept 25 mg twice weekly
0.1
0
4
8
12
16
20
24
Weeks
q8w, every 8 weeks; EOW, every other week Simulations are based on Zhou H, et al. Int J Clin Pharmacol Ther. 2004;42:267–276 for etanercept; St Clair EW, et al. Arth Rheum. 2002;46:1451–1459 for infliximab; and data on file at Abbott for adalimumab
rilonacept, eta toclizumab belimumab, TACI-Ig, ofatumumab, ocrelizumab, etc ICOS inhibitors, etc
全面认识生物制剂
一大类药物, 发展迅猛, 已广泛用于临床 其间作用机制、疗效和副作用差异巨大, 即使在TNF抑
UCSF-SICCA
15
Choy EHS, Panayi GS. N Engl J Med. 2001;344:907-916.
生物制剂的作用及疗效
这些生物制剂的治疗作用好象是“定点爆破”或“生物导 弹”,“炸死”肿瘤坏死因子、阻止它们传递疾病“火种”, 使疾病扩散蔓延的作用,因而患者体内的病情活动就更易得到控制。